Statement of Changes in Beneficial Ownership - Form 4

Ownership Submission

FORM 4 Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response...0.5

1. Name and Address of Reporting Person * Mack David Henry 2. Issuer Name and Ticker or Trading Symbol PMV Pharmaceuticals, Inc. [PMVP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) President and CEO / (Last) (First) (Middle) C/O PMV PHARMACEUTICALS, INC. , ONE RESEARCH WAY 3. Date of Earliest Transaction (Month/Day/Year) (Street) PRINCETON NJ 08540 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Join/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code 4. Securities Acquired (A) or Disposed of (D) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) 6. Ownership Form: Direct (D) or Indirect (I) 7. Nature of Indirect Beneficial Ownership Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code	5. Number of Derivative Securities Acquired (A) or Disposed of (D)	6. Date Exercisable and Expiration Date	7. Title and Amount of Securities Underlying Derivative Security	8. Price of Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	11. Nature of Indirect Beneficial Ownership
Code	V	(A)	(D)	Date Exercisable	Expriation Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
Director	10% Owner	Officer	Other
Mack David Henry C/O PMV PHARMACEUTICALS, INC. ONE RESEARCH WAY PRINCETON, NJ08540			President and CEO

Signatures

/s/ Robert Ticktin, by power of attorney	2024-10-03
**Signature of Reporting Person	Date

Explanation of Responses:

(*)	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
(**)	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2021.
(2)	On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 134,584 shares of PMV common stock granted to the reporting person on May 12, 2021. In exchange, the reporting person received a replacement option, for 134,584 shares, having an exercise price of $1.48 per share.
(3)	Shares subject to the option vest in 48 equal monthly installments beginning on March 10, 2022.
(4)	On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 249,600 shares of PMV common stock granted to the reporting person on February 10, 2022. In exchange, the reporting person received a replacement option, for 249,600 shares, having an exercise price of $1.48 per share.
(5)	One-third of the shares subject to the option vest on August 13, 2025 and 1/36th vest monthly thereafter.
(6)	Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2023.
(7)	On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 330,000 shares of PMV common stock granted to the reporting person on May 12, 2023. In exchange, the reporting person received a replacement option, for 330,000 shares, having an exercise price of $1.48 per share.
(8)	One-fourth of the shares subject to the option vest on August 13, 2025 and 1/48th vest monthly thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Public link

Please use the above public link if you want to share this noodl on another website.